Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 1
3(60.0%)
Phase 2
2(40.0%)
5Total
Phase 1(3)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT04953962Phase 2Completed

Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer

Role: lead

NCT00700336Phase 1Completed

Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)

Role: lead

NCT03113188Phase 1Completed

CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors

Role: lead

NCT00942825Phase 2Completed

Triplet Combination First Line Treatment in Non Small Cell Lung Cancer (NSCLC)

Role: lead

NCT00551512Phase 1Completed

Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors

Role: lead

All 5 trials loaded